Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | ITK | Q08881 | 6/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043730 | 0.73 | RAB9A (0.49) | NPC1RAB9AITKKDM4EMEN1 | |
| SCHEMBL26598946 | 0.73 | METAP1 (0.51) | METAP1MEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL28399450 | 0.73 | RAB9A (0.61) | NPC1RAB9AITKKDM4EMEN1 | |
| SCHEMBL17799963 | 0.72 | SLC6A3 (0.49) | — | |
| SCHEMBL14012751 | 0.72 | KDR (0.54) | NPC1RAB9AITKKDM4EMEN1 | |
| SCHEMBL21174591 | 0.71 | METAP1 (0.57) | NPC1RAB9AMETAP1KDM4EMEN1 | |
| SCHEMBL384799 | 0.71 | METAP1 (0.61) | METAP1MEN1KMT2ALMNA | |
| SCHEMBL16404333 | 0.71 | METAP1 (0.61) | NPC1RAB9AMETAP1KDM4EMEN1 | |
| SCHEMBL27109712 | 0.70 | AURKA (0.54) | NPC1RAB9AITKKDM4EMEN1 | |
| SCHEMBL19136142 | 0.70 | METAP1 (0.51) | NPC1RAB9AMETAP1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
| CN-101460490-A | Substituted ring fused azines and their use in cancer therapy | AUCKLAND UNISERVICES LTD (NZ) | 2009-06-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | NPC1 1687/4885RAB9A 1026/4885ITK 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.